Myriad Genetics | MYGN - Cash And Equivalent


Myriad Genetics reported $145.4M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agilent USD 1.79B 254M Sep/2025
Becton, Dickinson and Co. USD 641M 94M Sep/2025
Bio-Rad Laboratories USD 395.8M 26.5M Sep/2025
Bruker USD 293.1M 201.1M Sep/2025
Danaher USD 4.62B 3.09B Dec/2025
Exact Sciences USD 789.04M 131.94M Sep/2025
Hologic USD 2.17B 208.5M Dec/2025
Illumina USD 1.05B 116M Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Mettler Toledo International USD 69.06M 7.24M Sep/2025
Myriad Genetics USD 145.4M 71M Sep/2025
Quest Diagnostics USD 432M 113M Sep/2025
Quidel USD 98.1M 53.6M Sep/2025
Repligen USD 748.75M 39.89M Sep/2025
Revvity USD 931.39M 60.46M Sep/2025
Standard Biotools USD 129.42M 29.2M Sep/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Veracyte USD 315.57M 96.07M Sep/2025
Waters USD 459.12M 91.9M Sep/2025